{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T13:28:45Z","timestamp":1786973325397,"version":"build-2736575974"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":73,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Health Functional Food Development Support Program","award":["RS2023-00282826"],"award-info":[{"award-number":["RS2023-00282826"]}]},{"DOI":"10.13039\/501100003705","name":"Korea Institute of Toxicology","doi-asserted-by":"publisher","award":["Grant No. 2710008773"],"award-info":[{"award-number":["Grant No. 2710008773"]}],"id":[{"id":"10.13039\/501100003705","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-56352-5","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T02:27:21Z","timestamp":1780626441000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bacillus subtilis pb2441 partially attenuates hepatic steatosis with transcriptomic changes broadly similar to dapagliflozin in a Western diet mouse model"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8310-7441","authenticated-orcid":false,"given":"Yangrae","family":"Cho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9661-6622","authenticated-orcid":false,"given":"Min-Kyu","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3443-8230","authenticated-orcid":false,"given":"Kyoung-Sik","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,5]]},"reference":[{"key":"56352_CR1","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.3350\/cmh.2022.0365","volume":"29","author":"ML Teng","year":"2023","unstructured":"Teng, M. L. et al. Global incidence and prevalence of nonalcoholic fatty liver disease. Clin. Mol. Hepatol. 29, S32\u2013S42. https:\/\/doi.org\/10.3350\/cmh.2022.0365 (2023).","journal-title":"Clin. Mol. Hepatol."},{"key":"56352_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/1755-1536-6-14","volume":"6","author":"L Longato","year":"2013","unstructured":"Longato, L. Non-alcoholic fatty liver disease (NAFLD): A tale of fat and sugar?. Fibrogenes. Tissue Repair 6, 14. https:\/\/doi.org\/10.1186\/1755-1536-6-14 (2013).","journal-title":"Fibrogenes. Tissue Repair"},{"key":"56352_CR3","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","volume":"67","author":"N Chalasani","year":"2018","unstructured":"Chalasani, N. et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology 67, 328\u2013357. https:\/\/doi.org\/10.1002\/hep.29367 (2018).","journal-title":"Hepatology"},{"key":"56352_CR4","doi-asserted-by":"publisher","unstructured":"European Association for the Study of the, L., European Association for the Study of, D. & European Association for the Study of, O. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 64, 1388-1402, https:\/\/doi.org\/10.1016\/j.jhep.2015.11.004 (2016).","DOI":"10.1016\/j.jhep.2015.11.004"},{"key":"56352_CR5","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/s0002-9343(99)00271-5","volume":"107","author":"G Marchesini","year":"1999","unstructured":"Marchesini, G. et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am. J. Med. 107, 450\u2013455. https:\/\/doi.org\/10.1016\/s0002-9343(99)00271-5 (1999).","journal-title":"Am. J. Med."},{"key":"56352_CR6","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1053\/jhep.2003.50161","volume":"37","author":"G Marchesini","year":"2003","unstructured":"Marchesini, G. et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37, 917\u2013923. https:\/\/doi.org\/10.1053\/jhep.2003.50161 (2003).","journal-title":"Hepatology"},{"key":"56352_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.labinv.2023.100129","volume":"103","author":"Q Zheng","year":"2023","unstructured":"Zheng, Q. et al. Comparison of animal models for the study of nonalcoholic fatty liver disease. Lab. Invest. 103, 100129. https:\/\/doi.org\/10.1016\/j.labinv.2023.100129 (2023).","journal-title":"Lab. Invest."},{"key":"56352_CR8","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202200346R","volume":"36","author":"CD Green","year":"2022","unstructured":"Green, C. D. et al. A new preclinical model of Western diet-induced progression of non-alcoholic steatohepatitis to hepatocellular carcinoma. FASEB J. 36, e22372. https:\/\/doi.org\/10.1096\/fj.202200346R (2022).","journal-title":"FASEB J."},{"key":"56352_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-35861-1","volume":"14","author":"M Yang","year":"2023","unstructured":"Yang, M. et al. Western diet contributes to the pathogenesis of non-alcoholic steatohepatitis in male mice via remodeling gut microbiota and increasing production of 2-oleoylglycerol. Nat. Commun. 14, 228. https:\/\/doi.org\/10.1038\/s41467-023-35861-1 (2023).","journal-title":"Nat. Commun."},{"key":"56352_CR10","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein, H. C. et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 394, 121\u2013130. https:\/\/doi.org\/10.1016\/S0140-6736(19)31149-3 (2019).","journal-title":"Lancet"},{"key":"56352_CR11","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso, S. P. et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 375, 1834\u20131844. https:\/\/doi.org\/10.1056\/NEJMoa1607141 (2016).","journal-title":"N. Engl. J. Med."},{"key":"56352_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/metabo11020087","author":"Z Szekeres","year":"2021","unstructured":"Szekeres, Z., Toth, K. & Szabados, E. The effects of SGLT2 inhibitors on lipid metabolism. Metabolites https:\/\/doi.org\/10.3390\/metabo11020087 (2021).","journal-title":"Metabolites"},{"key":"56352_CR13","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1080\/21623945.2021.1979277","volume":"10","author":"T Han","year":"2021","unstructured":"Han, T. et al. Sodium glucose cotransporter 2 inhibitor dapagliflozin depressed adiposity and ameliorated hepatic steatosis in high-fat diet induced obese mice. Adipocyte 10, 446\u2013455. https:\/\/doi.org\/10.1080\/21623945.2021.1979277 (2021).","journal-title":"Adipocyte"},{"key":"56352_CR14","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman, B. et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373, 2117\u20132128. https:\/\/doi.org\/10.1056\/NEJMoa1504720 (2015).","journal-title":"N. Engl. J. Med."},{"key":"56352_CR15","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray, J. J. V. et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N. Engl. J. Med. 381, 1995\u20132008. https:\/\/doi.org\/10.1056\/NEJMoa1911303 (2019).","journal-title":"N. Engl. J. Med."},{"key":"56352_CR16","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1056\/NEJMc1902837","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott, S. D., Raz, I. & Sabatine, M. S. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. Reply. N. Engl. J. Med. 380, 1881\u20131882. https:\/\/doi.org\/10.1056\/NEJMc1902837 (2019).","journal-title":"N. Engl. J. Med."},{"key":"56352_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.108503","volume":"104","author":"RM Hazem","year":"2022","unstructured":"Hazem, R. M., Ibrahim, A. Z., Ali, D. A. & Moustafa, Y. M. Dapagliflozin improves steatohepatitis in diabetic rats via inhibition of oxidative stress and inflammation. Int. Immunopharmacol. 104, 108503. https:\/\/doi.org\/10.1016\/j.intimp.2021.108503 (2022).","journal-title":"Int. Immunopharmacol."},{"key":"56352_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s40360-025-00898-z","volume":"26","author":"X Fan","year":"2025","unstructured":"Fan, X. et al. Dapagliflozin attenuates metabolic dysfunction-associated steatotic liver disease by inhibiting lipid accumulation, inflammation and liver fibrosis. BMC Pharmacol. Toxicol. 26, 59. https:\/\/doi.org\/10.1186\/s40360-025-00898-z (2025).","journal-title":"BMC Pharmacol. Toxicol."},{"key":"56352_CR19","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s40261-019-00785-6","volume":"39","author":"Y Arase","year":"2019","unstructured":"Arase, Y. et al. Effect of sodium glucose co-transporter 2 inhibitors on liver fat mass and body composition in patients with nonalcoholic fatty liver disease and type 2 diabetes mellitus. Clin. Drug Investig. 39, 631\u2013641. https:\/\/doi.org\/10.1007\/s40261-019-00785-6 (2019).","journal-title":"Clin. Drug Investig."},{"key":"56352_CR20","doi-asserted-by":"publisher","first-page":"339","DOI":"10.5114\/ceh.2020.102173","volume":"6","author":"M Dwinata","year":"2020","unstructured":"Dwinata, M., Putera, D. D., Hasan, I. & Raharjo, M. SGLT2 inhibitors for improving hepatic fibrosis and steatosis in non-alcoholic fatty liver disease complicated with type 2 diabetes mellitus: A systematic review. Clin. Exp. Hepatol. 6, 339\u2013346. https:\/\/doi.org\/10.5114\/ceh.2020.102173 (2020).","journal-title":"Clin. Exp. Hepatol."},{"key":"56352_CR21","doi-asserted-by":"publisher","DOI":"10.1177\/20420188241269178","volume":"15","author":"CJ Bailey","year":"2024","unstructured":"Bailey, C. J. Diabetes and gout: Another role for SGLT2 inhibitors?. Ther. Adv. Endocrinol. Metab. 15, 20420188241269178. https:\/\/doi.org\/10.1177\/20420188241269178 (2024).","journal-title":"Ther. Adv. Endocrinol. Metab."},{"key":"56352_CR22","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/S2213-8587(13)70050-0","volume":"1","author":"AA Tahrani","year":"2013","unstructured":"Tahrani, A. A., Barnett, A. H. & Bailey, C. J. SGLT inhibitors in management of diabetes. Lancet Diabetes Endocrinol. 1, 140\u2013151. https:\/\/doi.org\/10.1016\/S2213-8587(13)70050-0 (2013).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"56352_CR23","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/ajcn\/nqz042","volume":"110","author":"SR Sharpton","year":"2019","unstructured":"Sharpton, S. R., Maraj, B., Harding-Theobald, E., Vittinghoff, E. & Terrault, N. A. Gut microbiome-targeted therapies in nonalcoholic fatty liver disease: A systematic review, meta-analysis, and meta-regression. Am. J. Clin. Nutr. 110, 139\u2013149. https:\/\/doi.org\/10.1093\/ajcn\/nqz042 (2019).","journal-title":"Am. J. Clin. Nutr."},{"key":"56352_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1004559","volume":"11","author":"J Boursier","year":"2015","unstructured":"Boursier, J. & Diehl, A. M. Implication of gut microbiota in nonalcoholic fatty liver disease. PLoS Pathog. 11, e1004559. https:\/\/doi.org\/10.1371\/journal.ppat.1004559 (2015).","journal-title":"PLoS Pathog."},{"key":"56352_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/srep45176","volume":"7","author":"L Xue","year":"2017","unstructured":"Xue, L. et al. Probiotics may delay the progression of nonalcoholic fatty liver disease by restoring the gut microbiota structure and improving intestinal endotoxemia. Sci. Rep. 7, 45176. https:\/\/doi.org\/10.1038\/srep45176 (2017).","journal-title":"Sci. Rep."},{"key":"56352_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0210120","volume":"13","author":"B Kim","year":"2018","unstructured":"Kim, B. et al. Protective effects of Bacillus probiotics against high-fat diet-induced metabolic disorders in mice. PLoS ONE 13, e0210120. https:\/\/doi.org\/10.1371\/journal.pone.0210120 (2018).","journal-title":"PLoS ONE"},{"key":"56352_CR27","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.bbrc.2016.03.107","volume":"473","author":"B Kim","year":"2016","unstructured":"Kim, B. et al. Protective effects of Lactobacillus rhamnosus GG against dyslipidemia in high-fat diet-induced obese mice. Biochem. Biophys. Res. Commun. 473, 530\u2013536. https:\/\/doi.org\/10.1016\/j.bbrc.2016.03.107 (2016).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"56352_CR28","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1631\/jzus.B1400342","volume":"16","author":"K Lei","year":"2015","unstructured":"Lei, K. et al. Effect of dietary supplementation of Bacillus subtilis B10 on biochemical and molecular parameters in the serum and liver of high-fat diet-induced obese mice. J Zhejiang Univ Sci B. 16, 487\u2013495. https:\/\/doi.org\/10.1631\/jzus.B1400342 (2015).","journal-title":"J Zhejiang Univ Sci B."},{"key":"56352_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.589273","volume":"12","author":"L Li","year":"2021","unstructured":"Li, L. et al. Dapagliflozin alleviates hepatic steatosis by restoring autophagy via the AMPK-mTOR pathway. Front. Pharmacol. 12, 589273. https:\/\/doi.org\/10.3389\/fphar.2021.589273 (2021).","journal-title":"Front. Pharmacol."},{"key":"56352_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2021.174304","volume":"907","author":"J Luo","year":"2021","unstructured":"Luo, J. et al. Dapagliflozin attenuates steatosis in livers of high-fat diet-induced mice and oleic acid-treated L02 cells via regulating AMPK\/mTOR pathway. Eur. J. Pharmacol. 907, 174304. https:\/\/doi.org\/10.1016\/j.ejphar.2021.174304 (2021).","journal-title":"Eur. J. Pharmacol."},{"key":"56352_CR31","doi-asserted-by":"publisher","first-page":"3528","DOI":"10.1002\/eji.201040421","volume":"40","author":"M Vijay-Kumar","year":"2010","unstructured":"Vijay-Kumar, M., Carvalho, F. A., Aitken, J. D., Fifadara, N. H. & Gewirtz, A. T. TLR5 or NLRC4 is necessary and sufficient for promotion of humoral immunity by flagellin. Eur. J. Immunol. 40, 3528\u20133534. https:\/\/doi.org\/10.1002\/eji.201040421 (2010).","journal-title":"Eur. J. Immunol."},{"key":"56352_CR32","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/nbt.3519","volume":"34","author":"NL Bray","year":"2016","unstructured":"Bray, N. L., Pimentel, H., Melsted, P. & Pachter, L. Near-optimal probabilistic RNA-seq quantification. Nat. Biotechnol. 34, 525\u2013527. https:\/\/doi.org\/10.1038\/nbt.3519 (2016).","journal-title":"Nat. Biotechnol."},{"key":"56352_CR33","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.7563.2","volume":"4","author":"C Soneson","year":"2015","unstructured":"Soneson, C., Love, M. I. & Robinson, M. D. Differential analyses for RNA-seq: Transcript-level estimates improve gene-level inferences. F1000Res 4, 1521. https:\/\/doi.org\/10.12688\/f1000research.7563.2 (2015).","journal-title":"F1000Res"},{"key":"56352_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550. https:\/\/doi.org\/10.1186\/s13059-014-0550-8 (2014).","journal-title":"Genome Biol."},{"key":"56352_CR35","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa, M. & Goto, S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27\u201330. https:\/\/doi.org\/10.1093\/nar\/28.1.27 (2000).","journal-title":"Nucleic Acids Res."},{"key":"56352_CR36","doi-asserted-by":"publisher","first-page":"W216","DOI":"10.1093\/nar\/gkac194","volume":"50","author":"BT Sherman","year":"2022","unstructured":"Sherman, B. T. et al. DAVID: A web server for functional enrichment analysis and functional annotation of gene lists (2021 update). Nucleic Acids Res. 50, W216\u2013W221. https:\/\/doi.org\/10.1093\/nar\/gkac194 (2022).","journal-title":"Nucleic Acids Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-56352-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-56352-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-56352-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T13:04:21Z","timestamp":1786971861000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-56352-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,5]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["56352"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-56352-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,5]]},"assertion":[{"value":"8 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"YC is a major stock holder of Proxenrem. Bacillus subtilis pb2441 is under a Korean patent application, but we have no restrictions on sharing the data in this manuscript. All authors declare no additional competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"25663"}}